179P Efficacy and safety of extended-interval dosing strategy of immune checkpoint inhibitors during the COVID-19 outbreak: Experience from a single center

Abstract

Background: Question emerged during COVID-19 pandemic to minimize the risk of nosocomial viral exposure. Pharmacokinetic modelling evidence supports extended-interval dosing of ICI in advanced NSCLC, showing equivalent pharmacological performance than standard schedule. However, there is a clear lack of clinical data.